Vectron Biosolutions AS is your expert on developing cost-effective microbial production processes for recombinant proteins

Do you need to cut manufacturing costs?

The manufacturing costs of many recombinant proteins can be significantly reduced through increasing titres and improving the solubility of the proteins, reducing the necessities of costly downstream processes. This is increasingly important in the competitive landscape of the biopharmaceutical industry, especially with the advent of biosimilars and biobetters, as well as for suppliers of industrial enzymes where the markets are smaller.

Vectron Biosolutions is your upstream expert on developing robust, cost-efficient production processes for recombinant proteins in E. coli and other bacteria. We have proprietary next-generation expression tools and decades of experience that is available to you through partnerships and licensing.

Latest news

  • Vectron makes changes to its Board of Directors

    June 17 | 2021

    With the closing of a Series A round with Dynamk Capital, Vectron adds Reinhard Vogt and Trond Erik Vee Aune as new board members.

  • Vectron closes Series A investment with Dynamk Capital

    June 17 | 2021

    Vectron announces the closing of a Series A round financing with Dynamk Capital

    Read more
  • Vectron acquires T3S Technologies' secretion platform

    June 17 | 2021

    Vectron announces the acquisition of T3S's bacterial secretion platform.

    Read more
  • New scientific paper

    June 22 | 2020

    We have recently co-authored a great new paper on translocation.

    Read more
Complete newslist


  • Bio-Europe Spring (virtual)

    Oct 25–28 | 2021
  • CPhI International; Milano, Italy

    Nov 09–11 | 2021
Meet us there!
More events